Pediatric Research

 
Stock Quotes for Pediatric Research top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
  • Stock Type: Slow Growth
Sign-up for cpdu investment picks

 
News Articles for Pediatric Research top ^
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented new data from an integrated analysis of survival from two open-label, Phase 2 studies of asfotase alfa in pediatric patients (ages ≤5 years at enrollment) with hypophosphatasia (HPP) compared with data from a retrospective natural history study of untreated historical control patients matched for age and disease severity.
Sign-up for Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years investment picks
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product (Lagova) to treat pediatric growth hormone deficiency disorder (GHD). All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment.
Sign-up for OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder investment picks
SOUTH SAN FRANCISCO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) for Qinprezo™ (vosaroxin), Sunesis' lead drug candidate.
Sign-up for Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo(TM) (Vosaroxin) for AML investment picks
NextGen Healthcare Information Systems, LLC.
Sign-up for NextGen Healthcare Partners with North Carolina Pediatric Associates for Deployment of Single Sign-on Solution investment picks
-- Smaller-Sized Stapler Gives Pediatric Surgeons the Size They Have Been Waiting for --
Sign-up for Cardica's Microcutter Xchange® 30 At Annual Meeting Of The American Pediatric Surgical Association investment picks
IRVINE, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) , a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its chromosomal microarray analysis (CMA) test to identify development disorders in pediatric patients, the CombiSNP™ Array for Pediatric Analysis , has received conditional approval from the New York Department of Health for testing on patient samples.
Sign-up for CombiMatrix's Pediatric Development Disorders Analysis Test Granted Conditional Approval From New York State Department of Health investment picks
HOUSTON, July 21, 2014 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) ("Whitestone"), a fully integrated real estate company that owns, operates and re-develops Community Centered Properties TM , announced the opening of the fifth location of Goodnight Pediatrics, an all-night children's urgent care facility, at its Gilbert Tuscany Village Property.
Sign-up for Whitestone REIT Welcomes Goodnight Pediatrics to Gilbert Tuscany Village investment picks
HOUSTON , June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal ® ) and Antineoplaston AS2-1 injections (Astugenal ® ), at the 16 th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2 , 2014.
Sign-up for Burzynski Research Institute, Inc. Announces Presentations at the 16th International Symposium on Pediatric Neuro-Oncology investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas.
Sign-up for Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting investment picks
NEW YORK and LONDON, June 17, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX) , an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
Sign-up for Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients investment picks
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp.
Sign-up for Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients investment picks
Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug Administration (FDA) has granted pediatric exclusivity for memantine hydrochloride.
Sign-up for Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR® investment picks
NOVATO, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU investment picks
Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric patients.
Sign-up for Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease investment picks
OPKO Health, Inc. (NYSE: OPK), today announced that the abstract “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)” has been selected for late breaking oral presentation at the 53rd Annual Meeting of the European Society of Paediatric Endocrinology (ESPE) on September 20, 2014 in Dublin, Ireland.
Sign-up for Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference investment picks
2014/6/25
Books-A-Million, Inc., has released ‘50 Books To Read Before You’re 5,’ a recommended reading list perfect for families eager to enjoy the world’s most beloved works of kid’s fiction.
Sign-up for Books-A-Million’s ‘50 Books To Read Before You’re 5’ Embraces American Academy of Pediatrics Recommendation investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Pediatric Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Peak Energy  |  Next: Peer Companies